Physician profile
Barbara Davis
NPI 1295059087
$2,770.50
in general payments reported to CMS, 2019-2025
19 companies · $913 in 2025
The $913 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.81 · 2023: $601 · 2024: $1,209 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,722.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.84 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $494.56 | 2023-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $276.52 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $212.20 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $204.88 | 2024-2025 | Cobenfy |
| Livanova USA, INC. | $203.51 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Almatica Pharma LLC | $124.06 | 2023-2025 | Loreev Xr |
| Lundbeck LLC | $109.40 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $108.89 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $97.45 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $87.97 | 2023-2025 | Trintellix |
| Alkermes, INC. | $79.85 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Neos Therapeutics, LP | $50.17 | 2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $31.92 | 2024-2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $21.08 | 2023 | Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $18.81 | 2023 | |
| Idorsia Pharmaceuticals US INC | $17.32 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $14.95 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $13.12 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.